Jun Gong, MD

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Jun Gong, MD, gives his perspective on neoadjuvant chemotherapy in elderly patients with muscle-invasive bladder cancer.

The conversation with Jun Gong, MD, focused on the evolving relationship between oncologists who treat prostate cancer and genetic counselors.

Jun Gong, MD, gives his perspective on a review article published in ONCOLOGY about the necessary relationship between medical oncologists and genetic counselors to help treat patients with prostate cancer.

On this week’s podcast, Jun Gong, MD, spoke with CancerNetwork® about the potential role of plasma glutamine as a biomarker for patients with localized prostate cancer.

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.